01 15Abraxane
02 3Abraxane
03 1Abraxane - BMS
04 1Abraxane - Celgene
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 1,247
2019 Revenue in Millions : 1,086
Growth (%) : 15
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 1,181
2020 Revenue in Millions : 1,247
Growth (%) : -5
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 0
2020 Revenue in Millions : 19
Growth (%) : -100
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 292
2019 Revenue in Millions : 275
Growth (%) : 6
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 242
2020 Revenue in Millions : 280
Growth (%) : -7
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 153
2021 Revenue in Millions : 242
Growth (%) : -37
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 811
2021 Revenue in Millions : 1,181
Growth (%) : -31
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 1,004
2022 Revenue in Millions : 811
Growth (%) : 24
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 213
2022 Revenue in Millions : 153
Growth (%) : 58
Main Therapeutic Indication : Oncology
Currency : USD
2015 Revenue in Millions : 848
2014 Revenue in Millions : 968
Growth (%) : 14%
